GAIN Begins (Part 2): Infectious Disease Society and Start-Up Companies Push for More
This article was originally published in RPM Report
Executive Summary
The ink is barely dry on new antibiotic incentives in the GAIN Act, but the anti-infective development community is pushing for more. New ideas include “pull” incentives modeled on biodefense programs.
You may also be interested in...
Antibiotic Incentive Legislation: Can Reimbursement Horn In?
There are two antibiotic incentive bills vying for attention in Congress. One is a follow-on to the popular GAIN Act; the other takes a new path – creating generous reimbursement formulas to help the next wave of anti-infectives find a successful niche in hospital market.
Regulatory Pathway for Achaogen Looks Better; Is It Aimed At Viable Commercial Market?
With the FDA bottleneck for new anti-infectives showing signs of improvement, the next concern is whether providers will pay high premiums for new anti-infectives and the related challenge of finding the right patients to make high-cost treatments make sense.
An Antibiotic Anniversary Celebration: Deal-Making and Investment Are Active In Formerly Moribund Field
A year ago, the Pew Trust hosted a meeting on antibiotic development that emphasized the many barriers still discouraging investment in the field despite new legislation (the GAIN Act). Three coincidental announcements in early 2014 show that the development freeze in anti-infectives is beginning to thaw.